Literature DB >> 4073860

Activity of selenazofurin against influenza A and B viruses in vitro.

R W Sidwell, J H Huffman, E W Call, H Alaghamandan, P D Cook, R K Robins.   

Abstract

Activity of the new antiviral compound selenazofurin was compared with the known active compounds ribavirin and amantadine against influenza A and B viruses. In experiments with Madin Darby canine kidney cells, selenazofurin inhibited the cytopathic effect and yield of influenza A/NWS/33 virus, with 50% effective dose ranges of 0.7 to 1.4 micrograms/ml (virus rating [VR], 1.3 to 1.4). The 50% effective dose range for ribavirin was 1.2 to 1.6 micrograms/ml (VR, 1.0 to 1.3), and for amantadine it was 9 micrograms/ml (VR, 0.9). Selenazofurin and ribavirin were similarly inhibitory to influenza B/Lee/40 virus, whereas amantadine was inactive. Selenazofurin appeared somewhat cytotoxic in these studies at concentrations as low as 1 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4073860      PMCID: PMC180256          DOI: 10.1128/AAC.28.3.375

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Use of disposable micro tissue culture plates for antiviral and interferon induction studies.

Authors:  R W Sidwell; J H Huffman
Journal:  Appl Microbiol       Date:  1971-11

2.  Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers.

Authors:  C R Magnussen; R G Douglas; R F Betts; F K Roth; M P Meagher
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

3.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

4.  Ribavirin small-particle aerosol treatment of influenza.

Authors:  V Knight; H W McClung; S Z Wilson; B K Waters; J M Quarles; R W Cameron; S E Greggs; J M Zerwas; R B Couch
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

5.  Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.

Authors:  J J Kirsi; J A North; P A McKernan; B K Murray; P G Canonico; J W Huggins; P C Srivastava; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  Synthesis and antitumor activity of 2-beta-D-ribofuranosylselenazole-4- carboxamide and related derivatives.

Authors:  P C Srivastava; R K Robins
Journal:  J Med Chem       Date:  1983-03       Impact factor: 7.446

7.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

8.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

9.  Ribavirin aerosol treatment of influenza B virus infection.

Authors:  H W McClung; V Knight; B E Gilbert; S Z Wilson; J M Quarles; G W Divine
Journal:  JAMA       Date:  1983-05-20       Impact factor: 56.272

10.  Suppression by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) of influenza virus-induced infections in mice.

Authors:  G P Khare; R W Sidwell; J T Witkowski; L N Simon; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

  10 in total
  3 in total

1.  Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.

Authors:  D B Mendel; C Y Tai; P A Escarpe; W Li; R W Sidwell; J H Huffman; C Sweet; K J Jakeman; J Merson; S A Lacy; W Lew; M A Williams; L Zhang; M S Chen; N Bischofberger; C U Kim
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

2.  Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro.

Authors:  S Shigeta; K Konno; T Yokota; K Nakamura; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

Review 3.  The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design.

Authors:  Annelies Stevaert; Lieve Naesens
Journal:  Med Res Rev       Date:  2016-08-29       Impact factor: 12.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.